A STUDY ON ANTICOAGULANTS IN CONTINUOUS HEMOFILTRATION (CHF)

Abstract

Bleeding complication caused by anticoagulant is a serious complication of CHF. The present study was undertaken to investigate relationship between various anticoagulantsand the incidence of bleeding complication during CHF and to decide optimal dose of the anticoagulant. The bleeding incidences with heparin, low molecular weight heparin and nafamostat mesilate were 7/11(64%), 3/15(20%) and 0/7(0%), respectively, indicating low molecular weight heparin and nafamostat mesilate should be chosen as anticoagulant for CHF. The optimal dose of those anticoagulant were less than 2.5unit/kg/hr and 0.1mg/kg/hr, respectively.